Article
Thrombin mutant W215A/E217A treatment improves neurological outcome and reduces cerebral infarct size in a mouse model of ischemic stroke.
Stroke - 1 Jun 2011
Berny-Lang Michelle A, Hurst Sawan, Tucker Erik I, Pelc Leslie A, Wang Ruikang K, Hurn Patricia D, Di Cera Enrico, McCarty Owen J T, Gruber András
Abstract excerpt
BACKGROUND AND PURPOSE: Treatment of ischemic stroke by activation of endogenous plasminogen using tissue plasminogen activator is limited by bleeding side effects. In mice, treatment of experimental ischemic stroke with activated protein C improves outcomes; however, activated protein C also has bleeding side effects. In contrast, activation of endogenous protein C using thrombin mutant W215A/E217A (WE) is...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.